Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

208
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
208

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early bone health assessment is indicated in Parkinson's: Risk factor analysis in a UK population-based cohort study.

Journal of Parkinson's disease·2026
Same author

Addressing Gaps in Parkinson's Disease Etiology: The Need for a Polyexposure Score.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Genetics to Improve Outcomes in Schizophrenia (GENios): A within-case molecular genetic study protocol.

PloS one·2026
Same author

Multicentre validation of a patient-reported outcome measure for functional movement disorders.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).

Movement disorders : official journal of the Movement Disorder Society·2025

Related Experiment Video

Updated: Mar 31, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.5K

Tracking Parkinson's: Study Design and Baseline Patient Data.

Naveed Malek1, Diane M A Swallow1, Katherine A Grosset1

  • 1Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK.

Journal of Parkinson'S Disease
|October 21, 2015
PubMed
Summary

This study established a large Parkinson's disease (PD) cohort to investigate clinical and genetic variations. The findings will help understand PD heterogeneity and guide future biomarker research.

Keywords:
Parkinson’s diseasegenotypeheterogeneityphenotype

More Related Videos

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.5K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

23.3K

Related Experiment Videos

Last Updated: Mar 31, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.5K
Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.5K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

23.3K

Area of Science:

  • Neuroscience
  • Epidemiology
  • Genetics

Background:

  • Parkinson's disease (PD) exhibits significant variability in clinical presentation.
  • This heterogeneity is influenced by both genetic factors and epidemiological elements.

Purpose of the Study:

  • To define and explain the variations in the clinical phenotype of Parkinson's disease.
  • To correlate clinical variations with genotypic differences in PD patients.

Main Methods:

  • The Tracking Parkinson's study is a multicenter, prospective, longitudinal epidemiological and biomarker study.
  • Enrolled patients with recent-onset (<3.5 years) and young-onset (<50 years) PD from UK specialist clinics.
  • Collected motor, non-motor, and quality of life data using validated scales, with follow-up assessments.

Main Results:

  • Recruited 2247 PD cases (1987 recent-onset, 260 young-onset).
  • Detailed baseline clinical data including age, sex, disease duration, MDS-UPDRS scores, LEDD, and PDQ-8 scores were collected for both groups.
  • Young-onset PD patients presented with distinct baseline characteristics compared to recent-onset cases.

Conclusions:

  • Established a large, demographically representative clinical PD cohort.
  • The cohort is designed to evaluate variations in clinical expression related to genetic influences.
  • Provides a platform for future imaging and biomarker research in Parkinson's disease.